Literature DB >> 7429641

Further studies of the neuraminidase content of inactivated influenza vaccines and the neuraminidase antibody responses after vaccination of immunologically primed and unprimed populations.

A P Kendal, F M Bozeman, F A Ennis.   

Abstract

Purified concentrates of influenza A/USSR/90/77(H1N1)-like, A/Texas/1/77 (H3N2)-like, and B/Hong Kong/5/72-like viruses used for preparation of investigational and licensed vaccines in 1978 to 1979 were tested for their content of neuraminidase enzyme activity. Concentrates of H1N1 virus used to prepare vaccines for clinical investigations performed in the spring of 1978 had neuraminidase activity at that time which decreased during storage to almost undetectable levels (three lots) or by 50% (one lot) by the winter of 1978. Several other lots of concentrates prepared with H1N1 virus and used for vaccine formulation had no detectable neuraminidase enzyme activity when tested in the winter of 1978, at a time when they would be administered in vaccines. The range of specific activity for different lots of concentrates was about 40-fold for A/Texas/1/77, B/Hong Kong/5/72, and A/USSR/90/77 neuraminidases. Immunogenicity of investigational vaccines prepared with tested concentrates and administered between April and July 1978 was measured in volunteers aged 13 to >50 years. Frequency of neuraminidase antibody rises to two doses of H1N1-containing vaccine was 10% in unprimed subjects aged <26 years and about 18 to 36% in older persons. The frequency of neuraminidase antibody rises to one dose of H3N2-containing vaccine varied from 0 to 32% in different groups (mean, 18%). The frequencies of neuraminidase antibody responses were always much lower than the frequencies of hemagglutinin antibody responses. These observations confirm the existence of practical difficulties in achieving uniformity of the neuraminidase content in influenza vaccines and of ensuring good immunogenicity of vaccine neuraminidase even in primed populations.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7429641      PMCID: PMC551225          DOI: 10.1128/iai.29.3.966-971.1980

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  22 in total

1.  Effect of neuraminidase antibody on Hong Kong influenza.

Authors:  A S Monto; A P Kendal
Journal:  Lancet       Date:  1973-03-24       Impact factor: 79.321

2.  Antineuraminidase antibody response of man to influenza virus neuraminidase N2: results obtained with an improved hemagglutination inhibition technique and an enzyme inhibition test.

Authors:  A V Hennessy; E Minuse; F M Davenport
Journal:  J Immunol       Date:  1972-08       Impact factor: 5.422

3.  Association of serum anti-neuraminidase antibody with resistance to influenza in man.

Authors:  B R Murphy; J A Kasel; R M Chanock
Journal:  N Engl J Med       Date:  1972-06-22       Impact factor: 91.245

4.  Studies with avian influenza A viruses: cross protection experiments in chickens.

Authors:  W H Allan; C R Madeley; A P Kendal
Journal:  J Gen Virol       Date:  1971-08       Impact factor: 3.891

5.  Undisturbed release of influenza virus in the presence of univalent antineuraminidase antibodies.

Authors:  H Brecht; U Hämmerling; R Rott
Journal:  Virology       Date:  1971-11       Impact factor: 3.616

6.  Flocculation of influenza virus by specific anti-neuraminidase antibody.

Authors:  A P Kendal; C R Madeley
Journal:  Arch Gesamte Virusforsch       Date:  1970

7.  Preparation and properties of antibody directed specifically against the neuraminidase of influenza virus.

Authors:  R G Webster; W G Laver
Journal:  J Immunol       Date:  1967-07       Impact factor: 5.422

8.  Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice.

Authors:  J L Schulman; M Khakpour; E D Kilbourne
Journal:  J Virol       Date:  1968-08       Impact factor: 5.103

9.  Antiviral activity of antiserum specific for an influenza virus neuraminidase.

Authors:  E D Kilbourne; W G Laver; J L Schulman; R G Webster
Journal:  J Virol       Date:  1968-04       Impact factor: 5.103

10.  Reduction in plaque size and reduction in plaque number as differing indices of influenza virus-antibody reactions.

Authors:  R I Jahiel; E D Kilbourne
Journal:  J Bacteriol       Date:  1966-11       Impact factor: 3.490

View more
  15 in total

1.  Biological and protective properties of immune sera directed to the influenza virus neuraminidase.

Authors:  Stefan J Halbherr; Thomas H Ludersdorfer; Meret Ricklin; Samira Locher; Marianne Berger Rentsch; Artur Summerfield; Gert Zimmer
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

2.  Neuraminidase-specific antibody responses to inactivated influenza virus vaccine in young and elderly adults.

Authors:  D C Powers; E D Kilbourne; B E Johansson
Journal:  Clin Diagn Lab Immunol       Date:  1996-09

Review 3.  Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines.

Authors:  Glendie Marcelin; Matthew R Sandbulte; Richard J Webby
Journal:  Rev Med Virol       Date:  2012-03-22       Impact factor: 6.989

4.  Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferrets.

Authors:  Berend Jan Bosch; Rogier Bodewes; Robert P de Vries; Joost H C M Kreijtz; Willem Bartelink; Geert van Amerongen; Guus F Rimmelzwaan; Cornelis A M de Haan; Albert D M E Osterhaus; Peter J M Rottier
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

Review 5.  [Guillain-Barré syndrome after exposure to influenza].

Authors:  H-P Hartung; B Keller-Stanislawski; R A Hughes; H C Lehmann
Journal:  Nervenarzt       Date:  2012-06       Impact factor: 1.214

6.  Development of neuraminidase subtype-specific reference antisera by recombinant protein expressed in baculovirus.

Authors:  Kyu-Jun Lee; Jun-Gu Choi; Hyun-Mi Kang; Kwang-Il Kim; Choi-Kyu Park; Youn-Jeong Lee
Journal:  Clin Vaccine Immunol       Date:  2012-12-05

7.  Randomized comparative study of the serum antihemagglutinin and antineuraminidase antibody responses to six licensed trivalent influenza vaccines.

Authors:  Robert B Couch; Robert L Atmar; Wendy A Keitel; John M Quarles; Janet Wells; Nancy Arden; Diane Niño
Journal:  Vaccine       Date:  2012-10-26       Impact factor: 3.641

8.  Antibody responses after repeated influenza A virus immunizations among schoolchildren in Japan.

Authors:  N Yamane; M Hiratsuka; J Arikawa; T Odagiri; N Ishida
Journal:  J Hyg (Lond)       Date:  1981-12

9.  A contributing role for anti-neuraminidase antibodies on immunity to pandemic H1N1 2009 influenza A virus.

Authors:  Glendie Marcelin; Rebecca DuBois; Adam Rubrum; Charles J Russell; Janet E McElhaney; Richard J Webby
Journal:  PLoS One       Date:  2011-10-24       Impact factor: 3.240

Review 10.  Targeting Antigens for Universal Influenza Vaccine Development.

Authors:  Quyen-Thi Nguyen; Young-Ki Choi
Journal:  Viruses       Date:  2021-05-24       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.